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Background: Type 2 diabetes, obesity and insulin resistance are characterized by hypertriglyceridemia and ectopic
accumulation of lipids in liver and skeletal muscle. AGPAT6 encodes a novel glycerol-3 phosphate acyltransferase,
GPAT4, which catalyzes the first step in the de novo triglyceride synthesis. AGPAT6-deficient mice show lower weight
and resistance to diet- and genetically induced obesity. Here, we examined whether common or low-frequency
variants in AGPAT6 associate with type 2 diabetes or related metabolic traits in a Danish population.
Methods: Eleven variants selected by a candidate gene approach capturing the common and low-frequency
variation of AGPAT6 were genotyped in 12,068 Danes from four study populations of middle-aged individuals. The
case–control study involved 4,638 type 2 diabetic and 5,934 glucose-tolerant individuals, while studies of
quantitative metabolic traits were performed in 5,645 non-diabetic participants of the Inter99 Study.
Results: None of the eleven AGPAT6 variants were robustly associated with type 2 diabetes in the Danish case–control
study. Moreover, none of the AGPAT6 variants showed association with measures of obesity (waist circumference and
BMI), serum lipid concentrations, fasting or 2-h post-glucose load levels of plasma glucose and serum insulin, or
estimated indices of insulin secretion or insulin sensitivity.
Conclusions: Common and low-frequency variants in AGPAT6 do not significantly associate with type 2 diabetes
susceptibility, or influence related phenotypic traits such as obesity, dyslipidemia or indices of insulin sensitivity or
insulin secretion in the population studied.
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Lipid droplets are universal cellular organelles that store
neutral lipids, such as sterol esters and triglycerides. Lipid
droplets are the main reservoir of energy storage, and pro-
vide phospholipids for membrane synthesis, and protect
cells from the lipotoxic effects of unesterified lipids [1].
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reproduction in any medium, provided the ortype 2 diabetes, obesity and insulin resistance are charac-
terized by hypertriglyceridemia and ectopic lipid storage
in various non-adipose tissues. Thus, several studies have
reported an association between accumulation of intra-
myocellular triglycerides and insulin resistance [2-5], and
the excessive accumulation of lipids in skeletal muscle,
liver and heart and a potential lipotoxic effect on beta-
cells has been linked to the pathogenesis of insulin re-
sistance and type 2 diabetes [6-8]. Genetic and acquired
syndromes of lipodystrophy are characterized by the inabil-
ity to store lipids in adipose tissues. This causes hypertri-
glyceridemia and ectopic deposition of lipids in skeletal
muscle and liver, and is associated with severe insulin re-
sistance in the absence of obesity [9]. Variants in genesl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phospholipid and triglyceride biosynthesis or proteins reg-
ulating the formation of lipid droplets could potentially
disturb the balance between storage of lipids in adipose tis-
sues and ectopic lipid deposition in non-adipose tissues
as mentioned above [1,10], and hence contribute to the
pathogenesis of insulin resistance and type 2 diabetes.
The first committed step in de novo triglyceride syn-
thesis is the acylation of glycerol-3-phosphate leading to
the formation of lysophosphatidic acid [10]. This reaction,
which has been considered to be rate-limiting, is catalyzed
by glycerol-3-phosphate acyltransferases (GPATs), of which
four isoforms have been identified in mammals [10].
GPAT4, which is encoded by AGPAT6, is the most re-
cently identified GPAT [11,12]. It was initially classified as
a acylglycerol-3-phosphate O-acyltransferase (AGPAT),
but later studies found it to be the second microsomal
GPAT localized to the endoplasmatic reticulum [10,11]. In
mice, AGPAT6 is highly expressed in brown adipose tissue
(BAT), white adipose tissue (WAT) and liver [13,14],
whereas in humans, AGPAT6 mRNA seems to be more
ubiquitously expressed with the highest expression in
testis, and brain, but also in adipose tissues and skeletal
muscle [11,15]. Recent studies have reported that micro-
somal GPAT activity is enhanced by insulin, and that this
may involve insulin-stimulated phosphorylation of the
microsomal GPAT3 and GPAT4, implying their im-
portance in insulin action on lipogenesis [14]. Studies of
agpat6−/−knock-out mice have shown that loss of
GPAT4 activity causes a 25% reduction in body weight
and resistance to both diet- and genetically induced obes-
ity. This was associated with increased energy expend-
iture, reduced triglyceride storage in BAT and WAT and
liver, and subdermal lipodystrophy [10,12,13]. Based on
the lessons learned from the agpat6-deficient mice, we
hypothesized that variation in the human AGPAT6 may
associate with obesity, hypertriglyceridemia, insulin re-
sistance and type 2 diabetes susceptibility.
The aim of the present study was to investigate whether
common and low-frequency variation in AGPAT6, en-
coding a novel GPAT enzyme, GPAT4, was associated
with type 2 diabetes, obesity, dyslipidemia or indices of in-
sulin resistance and insulin secretion in a large Danish
population.
Methods
Participants In total 11 AGPAT6 variants were geno-
typed in 12,068 individuals ascertained from five different
Danish study groups: 1) The Inter99 cohort, which is a
population-based, randomized, non-pharmacological inter-
vention study of middle-aged individuals for the prevention
of ischaemic heart disease (n = 6,287) conducted at the
Research Centre for Prevention and Health in Glostrup,
Copenhagen (ClinicalTrials.gov ID-no: NCT00289237)[16]; 2) type 2 diabetic patients (n = 1,575) from the
population-based, ADDITION Denmark screening study
cohort (Anglo-Danish-Dutch Study of Intensive Treat-
ment in People with Screen-Detected Diabetes in Primary
Care) (ClinicalTrials.gov ID-no: NCT00237548) [17];
3) unrelated type 2 diabetic patients (n = 1,658) exam-
ined at the out-patient clinic at Steno Diabetes Center,
Copenhagen, Denmark; 4) a population-based group of
unrelated middle-aged individuals (n = 567) also sampled
at Steno Diabetes Center, and 5) a sample of type 2 diabetic
patients and age-matched non-diabetic control persons en-
rolled in the former Vejle County (n = 1,981). The type 2
diabetes inclusion criteria in all study groups fulfilled
the diagnostic criteria according to the WHO 1999.
Clinical characteristics of the five study groups are given
in Additional file 1: Table S1. All participants were Danes
by self-report and all gave informed written consent be-
fore participation. We do not have specific information
on ethnicity yet all study participants are of Danish
nationality. In other studies of the same study material
we have by chip genotyping data looked at population
outliers and did not observe ethnical population out-
liers [18]. The studies were performed in accordance with
the principles of the Helsinki Declaration and all studies
were approved by the local ethics committees (Ethical
Committee of Copenhagen: #KA 98155, #KA95117g,
#KA95117gm, #KA94092g, #KA96008; Ethical Committee
of Aarhus: #2000183; Ethical Committee of Region of
Southern Denmark: #S-20080097).
Type 2 diabetic patients from study groups 1 (n = 328),
2 (n = 1,575), 3 (n = 1,658), 4 (n = 47) and 5 (n = 1,030)
were included in the case–control studies. Control indi-
viduals had normal fasting glucose according to WHO
1999 criteria [19] (study group 5 (n = 951)) or had nor-
mal fasting glucose and normal glucose tolerance during
a standard 75 g OGTT (study groups 1 (n = 4,463) and 4
(n = 520)). No pre-diabetics were included in the study.
In total, the case–control studies included 4,638 type 2
diabetic and 5,934 control individuals. Studies of quanti-
tative traits were performed in 5,645 participants of the
Inter99 cohort excluding individuals with type 2 diabetes
and screen-detected type 2 diabetes.
SNP selection We performed tagging of the genomic re-
gion including AGPAT6 (HapMap release 27, Phase II + III,
Feb. 09, B36, CEU panel; Chr8:41,544 kb - 41,607 kb
(AGPAT6 position ± 10 kb)) using Haploview 4.2 (www.
broadinstitute.org/haploview). See LD plot of AGPAT6 in
Figure 1. Eleven SNPs captured all common variation with
minor allele frequency (MAF) above 5% (n = 10) and low-
frequency variation with MAF below 5% but above 1%
(n = 1) variation in AGPAT6 (r2 >0.8). The selected SNPs
have the following rs numbers: rs13252523, rs7357415,
rs2977860, rs11785763, rs999188, rs17600159, rs2977845,
rs10504041, rs12677439, rs6988044 and rs890220.
Figure 1 Linkage disequilibrium (LD) plot across AGPAT6. The box at the top shows the AGPAT6 gene with the location of the 28 SNPs included in
this study. The 11 tag SNPs are indicated by circles around the rs number of the SNPs. The LD plot is based on the measure of D’. Each diamond
indicates the pair wise magnitude of LD, with dark grey diamonds indicating strong LD (D’ > 0.8) and light grey: uninformative. LD: linkage disequilibrium
is the non-random association of alleles at two or more loci, not necessarily on the same chromosome. Linkage disequilibrium describes a situation in
which some combinations of alleles or genetic markers occur more or less frequently in a population than would be expected from a random formation
of haplotypes from alleles based on their frequencies.
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weight and height were measured in light indoor cloth-
ing and without shoes. Waist circumference was mea-
sured in the standing position midway between the iliac
crest and the lower costal margin. Blood samples were
drawn after a 12-h overnight fast. Serum insulin levels
were measured by using the AutoDELFIA insulin kit
(Perkin-Elmer, Wallac, Turku, Finland). Plasma glucose
was analyzed by a glucose oxidase method (Granutest;
Merck, Darmstadt, Germany). Serum triglyceride and
cholesterols were determined by enzymatic colorimetric
methods (GPO-PAP and CHOD-PAP, Roche Molecular
Biochemicals).
Derived estimates of insulin response and insulin sensi-
tivity from an OGTT Indices of oral glucose-stimulated
insulin secretion are reported as the insulinogenic indexcalculated as ([serum insulin30 min – serum insulin0 min
(pmol/l)]/[plasma glucose30 min (mmol/l)]), and the BIGTT-
acute insulin response (AIR) index. The surrogate measures
of insulin sensitivity (SI) are reported as the homeo-
stasis model assessment of insulin resistance (HOMA-IR),
Matsuda-SI, Stumvoll-SI, and BIGTT-SI, all calculated as
described previously [20-23]. The BIGTT indices, which
apply information on sex and BMI, combined with plasma
glucose and serum insulin during an OGTT, were calcu-
lated as reported [21].
Genotyping The eleven AGPAT6 variants were genotyped
using KASPar SNP Genotyping system (KBioscience,
Hoddesdon, UK). Success-rates of the genotyping were
above 95% for all 11 SNPs. Error rates were below 0.5%
for the 11 variants, as estimated from re-genotyping of
596 duplicate samples. The distribution of genotypes was
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Inter99 for all SNPs (p > 0.05).
Statistical power The statistical power in type 2 dia-
betes case–control studies were calculated using the
CaTS power calculator for large genetic association stud-
ies (available at http://www.sph.umich.edu/csg/abecasis/
cats/). The power calculations assumed a Bonferroni ad-
justed alpha-value of 0.05/11 = 0.0045, a disease prevalence
of 8% and MAFs 5-40% (Additional file 1: Figure S1).
Given the MAFs for the 11 investigated AGPAT6 variants
(4.0% - 46%), our study has statistical power of more than
80% to detect an odds ratio (OR) of 1.10 in a case–control
design for the most common variants (MAF ~ 40%),
whereas we have ~80% power to detect an OR of 1.20-1.25
for the lower frequency variants (MAF~ 5%). The statis-
tical power calculations for quantitative traits were per-
formed as previously described [15] and showed that we
have statistical power of 94% to detect an effect equal to a
fraction of a standard deviation of 0.08 for a SNP with a
MAF of 46%, while we had power 93% to detect an effect
equal to a fraction of a standard deviation of 0.20 in case of
a MAF 5%. Our power calculations do not allow any solid
conclusions. Additional file 1: Figure S1 is a graph showing
power for a range of OR’s and allele frequencies.
Statistics A case–control analysis of type 2 diabetes was
performed using logistic regression to examine differences
in genotypes assuming an additive genetic model with ad-
justment for sex and age. A general linear model was used
to test quantitative variables for differences between geno-
type groups applying an additive model adjusted for age
and sex. We also performed the analysis including BMI as
covariate, however that did not add any information to the
analysis and results are not shown. Values of serum insulin,
Matsuda-SI and Stumvoll-SI were logarithmically trans-
formed before analyses, since that was appropriate when
checked for normality of the residuals. A p-value below a
Bonferroni corrected threshold of 0.05/11 = 0.0045 was
considered to be significant, taking the 11 variants into ac-
count. All analyses were performed in RGui version 2.11.1
(available at http://www.r-project.org).
Results
Eleven common and low-frequency AGPAT6 variants
were genotyped in 12,068 Danish individuals All the 11
genotyped AGPAT6 variants were in low pairwise link-
age disequilibrium (r2 < 0.46).
In case–control settings, four of the variants, rs2977845,
rs10504041, rs6988044 and rs890220 were nominally asso-
ciated with type 2 diabetes, when examined in 4,638
type 2 diabetes and 5,934 control individuals (p < 0.05)
(Table 1). For all the variants we calculated OR for the
minor allele in a model adjusted for age and sex. Thus,
carriers of the minor allele of rs2977845 (OR1.18 [95% CI
1.01-1.37, p = 0.034]) had a nominally increased risk oftype 2 diabetes, while carriers of the minor alleles of
rs10504041 (OR 0.91 [95% CI 0.84-0.99, p = 0.030]),
rs6988044 (OR 0.87 [95% CI 0.76-0.99, p = 0.030]) and
rs890220 (OR 0.88 [95% CI 0.8-0.96, p = 0.0052]) showed
a nominally reduced susceptibility to type 2 diabetes.
However, after correction for multiple testing none of
the 11 variants were robustly associated with type 2 dia-
betes (Table 1). We performed lookup of the genotyped
SNPs in results from the newest DIAGRAM genome-
wide association study (http://diagram-consortium.org/
downloads.html) [24]. Seven of the 11 SNPs were found
in DIAGRAM results. For the correlated rs10504041 and
rs890220 SNPs nominal association in DIAGRAM data
was observed yet in the opposite direction compared to
the present data (Additional file 1: Table S11). The minor
G allele of rs17600159 showed nominal association in
DIAGRAM data (OR 1.10, P = 0.0041) but was not statis-
tical significant in the current data (OR 1.12, P = 0.09).
(Additional file 1: Table S2).
We investigated the relationships of the 11 AGPAT6 vari-
ants with quantitative metabolic traits in the population-
based Inter99 cohort of 5,645 non-diabetic Danes.
Based on its function as GPAT4 and lessons learned
from agpat6-deficient mice, we focused on measures of
obesity (BMI and waist), dyslipidemia (triglycerides,
HDL-cholesterol and total-cholesterol), fasting and 2-h
post-glucose load levels of insulin or glucose, and
OGTT-derived indices of insulin sensitivity (HOMA-IR,
BIGTT-SI, Stumvoll-SI, Matsuda SI) and insulin secretion
(Insulinogenic index and BIGTT-AIR). All variants were
analysed applying an additive genetic model adjusting for
age and sex. The minor G-allele of rs17600159 showed
nominal association with plasma glucose and insulin 2-h
after an OGTT (Table 2). However, this was not significant
after correction for multiple testing. For the minor A-allele
of rs890220, which showed the most significant nominal
association with type 2 diabetes, we observed no associ-
ation with any of the examined metabolic traits (Table 3).
Moreover, we could not demonstrate any association
of the other nine AGPAT6 variants with these traits of
obesity, dyslipidemia, insulin sensitivity or insulin secretion
(Additional file 1: Tables S3–11). Adjustment for BMI in
all analysis did not change the results substantially.
Discussion
Several studies have shown that ectopic deposition of
triglycerides in lipid droplets is strongly associated with
insulin resistance and plays an important role in the
pathogenesis of type 2 diabetes [6-8,25]. This suggests
that variation in genes related to de novo triglyceride
synthesis and lipid droplet formation could be associated
with type 2 diabetes or related metabolic traits. Here, we
have tested whether common or low-frequency variation
in AGPAT6, was associated with increased susceptibility
Table 1 Type 2 diabetes association for the 11 AGPAT6 variants genotyped in type 2 diabetic individuals and control
individuals with normal glucose tolerance
AGPAT6 variant N Minor:major
allele
MAF Odds ratio P-value
(95% CI)T2D NGT
(wildtype/hetero-/homozygous) (wildtype/hetero-/homozygous)
rs13252523 1428/2304/802 1821/2840/1148 G:A 0.44 0.95 (0.88-1.01) 0.098
rs7357415 2779/1555/197 3546/1973/293 T:A 0.22 0.95 (0.87-1.03) 0.19
rs2977860 2158/1931/386 2827/2419/478 T:C 0.30 1.03 (0.95-1.1) 0.49
rs11785763 3364/1095/94 4307/1405/116 G:A 0.14 0.99 (0.90-1.08) 0.79
rs999188 1379/2271/875 1802/2817/1169 T:G 0.44 1.00 (0.94-1.07) 0.98
rs17600159 3941/581/13 5123/658/16 G:A 0.063 1.12 (0.98-1.29) 0.092
rs2977845 4124/433/12 5332/513/15 G:A 0.048 1.18 (1.01-1.37) 0.034
rs10504041 2980/1359/169 3738/1814/256 G:A 0.19 0.91 (0.84-0.99) 0.030
rs12677439 2568/1709/271 3374/2062/343 T:C 0.24 1.06 (0.99-1.15) 0.11
rs6988044 3993/566/15 5028/786/31 G:A 0.069 0.87 (0.76-0.99) 0.030
rs890220 3376/1107/85 4188/1468/151 G:A 0.15 0.88 (0.80-0.96) 0.0052
P-values and odds ratios were calculated by logistic regression analysis assuming an additive genetic model and adjusting for age and sex. Effects were calculated
for the minor allele. T2D Type 2 diabetes, NGT Normal glucose tolerance, MAF Minor allele frequency.
Table 2 Anthropometric and quantitative metabolic characteristics of 5,645 middle-aged Danish Inter99 participants
stratified according to the AGPAT6 rs17600159 genotype
AGPAT6 rs17600159 AA GA GG p value
N (men/women) 4835(2373/2462) 641(317/324) 19(10/9)
Age (years) 45.9 ± 7.9 45.8 ± 7.5 46.7 ± 7.9
Waist (cm) 85.9 ± 12.9 85.9 ± 12.9 90.7 ± 12.9 0.56
BMI (kg/m2) 26.0 ± 4.4 25.9 ± 4.4 27.8 ± 5.1 0.82
Serum Triglycerides (mmol/l) 1.3 ± 1.4 1.3 ± 1.1 1.2 ± 0.5 0.34
Serum Total cholesterol (mmol/l) 5.5 ± 1.1 5.5 ± 1.0 5.2 ± 1.0 0.92
Serum HDL cholesterol (mmol/l) 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.3 0.61
Plasma glucose (mmol/l)
Fasting 5.45 ± 0.51 5.47 ± 0.51 5.43 ± 0.55 0.36
120 min 5.93 ± 1.52 6.06 ± 1.64 6.76 ± 1.57 0.025
Serum insulin (pmol/l)
Fasting 41 ± 26 40.3 ± 24.4 41.8 ± 22.7 0.85
120 min 206 ± 198 212 ± 184 374 ± 410 0.013
Insulin secretion indices
Insulinogenic index 29.8 ± 19.7 30.2 ± 18.8 35.0 ± 30.4 0.32
BIGTT-AIR 1860 ± 1096 1859 ± 1017 2372 ± 2177 0.59
Insulin sensitivity indices
HOMA-IR (pmol x mmol/l) 9.98 ± 6.84 9.95 ± 6.42 10.09 ± 5.44 0.80
BIGTT-SI 9.49 ± 3.94 9.26 ± 3.94 7.97 ± 4.42 0.075
Stumvoll SI 0.10 ± 0.02 0.10 ± 0.02 0.09 ± 0.03 0.34
Matsuda SI 9.19 ± 5.69 8.94 ± 5.69 7.80 ± 4.56 0.15
Data are mean ± standard deviation. Values of serum insulin, the Stumvoll-SI and the Matsuda-SI were logarithmically transformed before analyses. P-values were
calculated assuming an additive genetic model with adjustment for age and sex.
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Table 3 Anthropometric and quantitative metabolic characteristics of 5,645 middle-aged Danish Inter99 participants
stratified according to the AGPAT6 rs890220 genotype
AGPAT6 rs890220 AA GA GG p value
N (men/women) 3995(1976/2019) 1368(654/714) 134(67/67)
Age (years) 45.8 ± 7.9 46.3 ± 7.7 45.9 ± 8.0
Waist (cm) 85.9 ± 13.0 86.1 ± 12.8 83.3 ± 12.1 0.48
BMI (kg/m2) 26.0 ± 4.5 26.1 ± 4.2 25.4 ± 4.0 0.60
Serum Triglycerides (mmol/l) 1.3 ± 1.5 1.3 ± 0.9 1.3 ± 1.2 0.50
Serum Total cholesterol (mmol/l) 5.5/-1.1 5.6 ± 1.0 5.5 ± 1.1 0.084
Serum HDL cholesterol (mmol/l) 1.4 ± 0.4 1.5 ± 0.4 1.4 ± 0.4 0.86
Plasma glucose (mmol/l)
Fasting 5.45 ± 0.52 5.47 ± 0.50 5.42 ± 0.50 0.74
120 min 5.95 ± 1.56 5.96 ± 1.51 5.76 ± 1.50 0.44
Serum insulin (pmol/l)
Fasting 41 ± 27 40 ± 25 39 ± 23 0.74
120 min 209 ± 199 201 ± 189 193 ± 146 0.63
Insulin secretion indices
Insulinogenic index 29.7 ± 19.3 30.0 ± 20.1 33.0 ± 23.1 0.22
BIGTT-AIR 1861 ± 1088 1852 ± 1067 1930 ± 1210 0.63
Insulin sensitivity indices
HOMA-IR (pmol x mmol/l) 10.03 ± 6.85 9.96 ± 6.796 9.58 ± 6.21 0.81
BIGTT-SI 9.44 ± 4.00 9.42 ± 3.79 9.54 ± 3.73 0.26
Stumvoll SI 0.10 ± 0.02 0.10 ± 0.02 0.10 ± 0.02 0.085
Matsuda SI 9.17 ± 5.78 9.04 ± 5.34 9.20 ± 6.47 0.85
Data are mean ± standard deviation. Values of serum insulin, the Stumvoll-SI and the Matsuda-SI were logarithmically transformed before analyses. P-values were
calculated assuming an additive genetic model with adjustment for age and sex.
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to our hypothesis, we could not demonstrate a robust
association with type 2 diabetes for any of the eleven
AGPAT6 variants investigated. Moreover, none of these
variants were significantly associated with measures of adi-
posity, dyslipidemia or indices of insulin sensitivity or
insulin secretion in a large cohort of non-diabetic, middle-
aged Danish individuals. These results indicate that com-
mon and low-frequency variation in the gene encoding
the most recently identified glycerol-3-phosphate acyl-
transferase, GPAT4, does not play a major role in the pres-
ence or absence of prediabetic phenotypes or risk of type
2 diabetes.
In previous genome-wide association (GWA) studies
of genetic variants contributing to type 2 diabetes risk
[26-29], the majority of genes investigated included only
variants with a MAF about 5% or higher. In none of these
studies, variants in genes regulating de novo phospholipid
or triglyceride synthesis or controlling lipid droplet for-
mation have been found to be robustly associated with
type 2 diabetes [30]. Here, we applied the candidate gene
approach to capture not only common but also low-
frequency variation in AGPAT6 to examine its potentialassociation with type 2 diabetes. However, in agreement
with the GWA-studies, we were unable to show any ro-
bust association of genetic variation in AGPAT6 with
type 2 diabetes in a Danish population. Yet, the statistical
power of the current study does not allow for solid con-
clusions on the possible existence of common AGPAT6
variants with modest or subtle effect on disease risk.
Also, this finding does not exclude that rare AGPAT6 var-
iants with a MAF less than 1% may cause type 2 diabetes
associated with e.g. lipodystrophy.
Studies of humans with acquired and genetic syn-
dromes of lipodystrophy have clearly shown that failure
of lipid storage in adipose tissues, hypertriglyceridemia
and ectopic deposition of lipid in liver and skeletal muscle
is associated with severe insulin resistance [9]. Mutations
in AGPAT2, which is another gene involved in de novo tri-
glyceride synthesis, is an accepted cause of congenital gen-
eralized lipodystrophy associated with extreme insulin
resistance and early onset diabetes in humans [31], and the
phenotype has been reproduced in agpat2-deficient mice
[32]. Moreover, accumulation of triglycerides in skeletal
muscle is negatively associated with insulin sensitivity even
in a healthy population [2-5]. These findings, together with
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of triglyceride in adipose tissues in agpat6-deficient mice,
suggested a possible role for variation in AGPAT6 in rela-
tion to prediabetic phenotypes such as obesity, circulating
levels of triglycerides and insulin resistance. However, at
least in a non-diabetic population of Danish individuals,
we were unable to demonstrate any significant association
of common and low-frequency variation in AGPAT6 with
these diabetes-related traits. These results are consistent
with the absence of AGPAT6 variants among genetic vari-
ants shown to contribute to dyslipidemia and hypertriglyc-
eridemia in current available GWA-studies [33].
The study has following limitations. First, the case–
control analysis is limited by sample size. We cannot ex-
clude association in our samples with odds ratios outside
of the 95% confidential intervals, i.e. for rs13252523, we
cannot exclude an association with type 2 diabetes with
on odds ratio higher than 1.01 or lower than 0.88. Sec-
ondly, although we corrected for multiple testing for the
11 variants, we did not correct for the number of pheno-
types since they are not independent, and therefore would
give an over-correction by Bonferroni. Another limitation
of the present study is that association of AGPAT6 variants
with insulin secretion and insulin sensitivity was based on
OGTT-derived surrogate measures of these traits rather
than application of gold-standard methods. A recent report
indicates that, in particular, caution is required for the inter-
pretation of differences in OGTT-derived values of insulin
sensitivity, because such differences may reflect variations
in beta-cell function rather than true variations in insulin
sensitivity [34]. It would also have been interesting to exam-
ine association of these AGPAT6 variants with direct or in-
direct measures of ectopic lipid content in relevant target
tissues such as liver and skeletal muscle, and with AGPAT6
expression and/or activity in these tissues. Nevertheless, so
far there is no evidence from GWA studies that common
variants in AGPAT6 associate with hepatic steatosis such
as seen in non-alcoholic fatty liver disease [35,36].
Conclusions
In summary, we here report that common and low-
frequency variation in AGPAT6 do not associate with
type 2 diabetes, or related obvious metabolic phenotypes
such as obesity, dyslipidemia or insulin resistance in a
Danish population. Further studies are warranted to ex-
clude a role for other genes involved in de novo trigly-
ceride synthesis and lipid droplet formation.
Additional file
Additional file 1: Figure S1. Graph for power for a range of lower ORs
and allele frequencies. Table S1 Clinical characteristics of the four study
groups. Data are means ± standard deviation. ∗, in the ADDITION study
fasting glucose is measured on capillary blood. T2D, type 2 diabetes.Table S2 Data on 7 of the SNPs from the newest DIAGRAM database.
OR’s are mean ± 95% CI. T2D, type 2 diabetes; NGT, normal glucose
tolerance; MAF, minor allele frequency. Table S3-S11 Anthropometric
and metabolic characteristics of 5,645 middle-aged Danish Inter99 participants
stratified according to AGPAT6 rs999188 (Table S2), 12677439 (Table S3),
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insulin, the Stumvoll-SI and the Matsuda-SI were logarithmically transformed
before analyses. P-values were calculated assuming an additive genetic
model with adjustment for age and sex.
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